These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34398492)

  • 1. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.
    Poynard T; Paradis V; Mullaert J; Deckmyn O; Gault N; Marcault E; Manchon P; Si Mohammed N; Parfait B; Ibberson M; Gautier JF; Boitard C; Czernichow S; Larger E; Drane F; Castille JM; Peta V; Brzustowski A; Terris B; Vallet-Pichard A; Roulot D; Laouénan C; Bedossa P; Castera L; Pol S; Valla D;
    Aliment Pharmacol Ther; 2021 Oct; 54(7):952-966. PubMed ID: 34398492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.
    Poynard T; Deckmyn O; Peta V; Paradis V; Gautier JF; Brzustowski A; Bedossa P; Castera L; Pol S; Valla D;
    Aliment Pharmacol Ther; 2023 Nov; 58(9):888-902. PubMed ID: 37642160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
    Bril F; McPhaul MJ; Caulfield MP; Castille JM; Poynard T; Soldevila-Pico C; Clark VC; Firpi-Morell RJ; Lai J; Cusi K
    J Investig Med; 2019 Feb; 67(2):303-311. PubMed ID: 30309884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.
    Poynard T; Peta V; Deckmyn O; Pais R; Ngo Y; Charlotte F; Ngo A; Munteanu M; Imbert-Bismut F; Monneret D; Housset C; Thabut D; Valla D; Boitard C; Castera L; Ratziu V;
    Eur J Gastroenterol Hepatol; 2020 Aug; 32(8):998-1007. PubMed ID: 31789950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
    Munteanu M; Tiniakos D; Anstee Q; Charlotte F; Marchesini G; Bugianesi E; Trauner M; Romero Gomez M; Oliveira C; Day C; Dufour JF; Bellentani S; Ngo Y; Traussnig S; Perazzo H; Deckmyn O; Bedossa P; Ratziu V; Poynard T;
    Aliment Pharmacol Ther; 2016 Oct; 44(8):877-89. PubMed ID: 27549244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study.
    Codjia T; Rebibo L; François A; Lagnel C; Huet E; Bekri S; Pattou F; Régimbeau JM; Schwarz L
    Obes Surg; 2021 Aug; 31(8):3548-3556. PubMed ID: 33844174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibromax and inflamatory markers cannot replace liver biopsy in the evaluation of non-alcoholic fatty liver disease.
    Lardi LL; Lul RM; Port GZ; Coral GP; Peres A; Dornelles GP; Branco F; Fernandes S; Leães CG; Mattos AA; Buss C; Tovo CV
    Minerva Gastroenterol (Torino); 2022 Mar; 68(1):85-90. PubMed ID: 32700499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
    Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
    Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.
    Poynard T; Lassailly G; Diaz E; Clement K; Caïazzo R; Tordjman J; Munteanu M; Perazzo H; Demol B; Callafe R; Pattou F; Charlotte F; Bedossa P; Mathurin P; Ratziu V;
    PLoS One; 2012; 7(3):e30325. PubMed ID: 22431959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
    Castera L; Garteiser P; Laouenan C; Vidal-Trécan T; Vallet-Pichard A; Manchon P; Paradis V; Czernichow S; Roulot D; Larger E; Pol S; Bedossa P; Correas JM; Valla D; Gautier JF; Van Beers BE;
    J Hepatol; 2024 Aug; 81(2):195-206. PubMed ID: 38548067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.
    Younes R; Rosso C; Petta S; Cucco M; Marietti M; Caviglia GP; Ciancio A; Abate ML; Cammà C; Smedile A; Craxì A; Saracco GM; Bugianesi E
    Liver Int; 2018 Apr; 38(4):715-723. PubMed ID: 29028281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
    Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D;
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort.
    Imajo K; Tetlow L; Dennis A; Shumbayawonda E; Mouchti S; Kendall TJ; Fryer E; Yamanaka S; Honda Y; Kessoku T; Ogawa Y; Yoneda M; Saito S; Kelly C; Kelly MD; Banerjee R; Nakajima A
    World J Gastroenterol; 2021 Feb; 27(7):609-623. PubMed ID: 33642832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.
    Davison BA; Harrison SA; Cotter G; Alkhouri N; Sanyal A; Edwards C; Colca JR; Iwashita J; Koch GG; Dittrich HC
    J Hepatol; 2020 Dec; 73(6):1322-1332. PubMed ID: 32610115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.
    Poynard T; Munteanu M; Charlotte F; Perazzo H; Ngo Y; Deckmyn O; Pais R; Merrouche W; de Ledinghen V; Mathurin P; Ratziu V;
    Eur J Gastroenterol Hepatol; 2018 May; 30(5):569-577. PubMed ID: 29406435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic Diagnosis of Nonalcoholic Fatty Liver Disease.
    Lai J; Wang HL; Zhang X; Wang H; Liu X
    Arch Pathol Lab Med; 2022 Aug; 146(8):940-946. PubMed ID: 34871361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
    Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
    J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
    Perazzo H; Munteanu M; Ngo Y; Lebray P; Seurat N; Rutka F; Couteau M; Jacqueminet S; Giral P; Monneret D; Imbert-Bismut F; Ratziu V; Hartemann-Huertier A; Housset C; Poynard T;
    Aliment Pharmacol Ther; 2014 Nov; 40(9):1081-93. PubMed ID: 25186086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.
    Weyler J; Verrijken A; Hornemann T; Vonghia L; Dirinck E; von Eckardstein A; Vanwolleghem T; Michielsen P; Peiffer F; Driessen A; Hubens G; Staels B; Francque S; Van Gaal L
    Acta Diabetol; 2021 Mar; 58(3):319-327. PubMed ID: 33084982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.